Trial · Interventional

Status unknownNot applicableRegistry data

Effect of Liraglutide on Weight Loss in Patients Who Have Undergone Revisional Bariatric Surgeries.

NCTNCT05285397Other idLiraglutide1

Open at ClinicalTrials.govAsk about this trial

Overview

Status: Status unknown
Phase: Not applicable
Enrollment: 60 participants (estimated)
Sponsor: General Committee of Teaching Hospitals and Institutes, Egypt · Other gov
Design: Randomized · Double masking
Countries: 1 country
Egypt
Start: 10 Mar 2022 (estimated)
Primary completion: Sept 2022 (estimated)
Completion: Sept 2022 (estimated)
First posted: 17 Mar 2022
Last update posted: 17 Mar 2022
Conditions: Morbid Obesity

Timeline

1 trial

Completed
Ongoing
Not yet recruiting
Stopped
Estimated dates (est.)
Results posted

20222023

N/A
Effect of Liraglutide on Weight Loss in Patients Who Have Undergone Revisional Bariatric Surgeries.
NCT05285397
est. 10 Mar 2022 to est. Sept 2022

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

Our primary objective is to assess the effect of Liraglutide on weight loss in patients who have undergone secondary bariatric surgeries. We set out to assess if Liraglutide is a viable option to augment weight loss in said category.

Interventions

Liraglutide Pen Injector [Saxenda]Drug

Arms2

Experimental
Liraglutide
drug starts 6 weeks post-operative until 6 months SC injection dose starting 0.6 mg/day and weekly up titrated until 3.0 mg/day
No intervention
Control
Patients with no weight loss drug intervention after bariatric surgery

Primary outcomes2

Outcomes the sponsor listed as primary.

Percentage Total weight loss
Time frame · 6 months
Percentage Excess body weight loss
Time frame · 6 months

Secondary outcomes(10)

Comorbidities
Time frame · 6 months
Weight
Time frame · 6 months
BMI
Time frame · 6 months
HbA1C
Time frame · 6 months
Fasting Blood Glucose (FBG)
Time frame · 6 months
HOMA-IR
Time frame · 6 months
Resolution of type 2 Diabetes Mellitus
Time frame · 6 months
Blood pressure
Time frame · 6 months
Lipid profile
Time frame · 6 months
Sleep apnea
Time frame · 6 months

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

A trial that is still running, or that stopped early, may post results later.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies1

Studies that cite this trial.

Studies with results

1 study on this page

Indexing hint: Randomized controlled trial · 2021

5 results

Liraglutide Augments Weight Loss After Laparoscopic Sleeve Gastrectomy: a Randomised, Double-Blind, Placebo-Control Study.

Thakur et al. 2021Obesity surgerycited by 42

PMID 32656729DOI 10.1007/s11695-020-04850-4PUB-32656729

Full text at the publisher5 results

Publisher page See results (5)

Eligibility

Who could join, as posted.

Sex: All
Age: Not stated
Healthy volunteers: Not accepted

Inclusion and exclusion criteria, as posted

Inclusion Criteria: * Undergone primary bariatric surgery * Need secondary bariatric surgery due to either weight regain (regained weight to have BMI \> 35) or medical associated diseases Exclusion Criteria: * Prior use of GLP-1 agonist * Past history of pancreatitis * Personal or family history of medullary thyroid cancer * Pregnancy or lactation * Acute coronary syndrome * Hepatic or renal dysfunction * Active malignancy

PepBank is a research reference. Talk to a doctor before you use any peptide.